Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Daily snipping by the shorts. Happens all the time with these OTC stocks thar RS. Expect to see additional dilution by end of year when the stock is struggling around 3.00 per share. IMO
Additional news........
https://finance.yahoo.com/news/relief-therapeutics-announces-swissmedic-approval-053000247.html
Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory
The state-of-the-art quality control and research and development laboratory in Balerna, Switzerland is run by APR Applied Pharma Research SA, a Relief Therapeutics subsidiary
GENEVA, SWITZERLAND / ACCESSWIRE / May 15, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF)(OTCQB:RLFFD)(OTCQB:RLFTD) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced its new state-of-the-art laboratory has been audited and approved by the Swiss Agency for Therapeutic Products (Swissmedic) and meets Good Manufacturing Practice (GMP) standards. Swissmedic is the national authorization and supervisory authority for drugs and medical products and devices.
The next-generation laboratory in Balerna, Switzerland is run by Relief Therapeutics' subsidiary APR Applied Pharma Research SA (APR) and offers a comprehensive suite of analytical and development services for internal projects and provides external clients with data and full documentation to meet current Good Manufacturing Practice (cGMP), International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) and international regulatory authority requirements.
"GMP compliance is a critical achievement for our laboratory, enabling us to create, safeguard and supply high-quality products to patients and healthcare providers as well as enable the future submissions of product files to regulatory authorities," said Paolo Galfetti, chief operating officer of Relief Therapeutics and chief executive officer of APR. "Our new GMP lab is designed to meet forthcoming pharmaceutical challenges and is fully integrated with the current technical and analytical R&D capabilities, with more than 800 m 2 equipped for analytical and formulation development of solid and non-solid dosage forms."
The modern analytical laboratory is part of APR's overall upgrade of the research and development facilities and equipment in Balerna, which now includes four new state-of-the-art high performance liquid chromatography (HPLC) systems equipped for method scouting, new analytical scales, viscometers, physical testing instruments as well as a new packaging area equipped with filling and blistering machines to pack research and development prototypes for stability studies.
"We are excited that our new GMP-compliant lab in Balerna, where innovation is driven by our experienced and highly talented employees, is now Swissmedic-approved and operational," said Jack Weinstein, chief executive officer of Relief Therapeutics. "APR is a trusted and experienced formulator and developer, which has been validated by the breadth and quality of its contract service partners and products that have been developed over more than 30 years."
....Oddly, IMHO, I would think that RFL would want this on their web site....if only in reference to APR ....... any explaination ?
Yes, its getting pretty stale. Or some of the existing long term holders are bailing. Really at a point where some great news would go a long way.
Need the mgmt / office holders to buy in here. That would be a huge statement for all the shareholders as would be some very positive news.
Here come the shorts,slowly creeping in after the RS. Never fails, bagholders..
Good morning Joe! I couldn’t agree with you more. Leo must have it too easy that he doesn’t appear to have any serious motivation for the companies well-being. My husband and I are driven every single day to make bigger and better things happen for our company and its employees. I’d love to see some fire in the belly here!!
IMHO....Relief needs to make some deals with some companies in counties like Switzerland, India and or Japan.
Any Approvals for ARDS would be huge......Whats the hold up ?
I wonder why some of the approvals by India can not be combined with Relief in order to market to other parts of the globe without the US involvement.
Further, I always thought that a RS would allow the big fund companies to buy in but so far its not looking that way. .
.
Right now is seems even the ticker symbols are a bit fuzzy to me.....
If uplisting to the nasdaq is a success then the RS will most likely bode well. If they are not successful in their uplisting attempt then it’s all for not…
Congrats on the 4 bagger......your intentions were sound, but alas the OTC mentality took over and you got out. Wise move, amigo.
Y'know, this was one of the very few OTC stocks that I actually bought into, back when COVID was thriving and every pharma company in the world was looking at vaccination and treatment. There was some news on their drug that caught my eye, I looked in here, found nothing really going on, bought it as a flyer. 2 days later, it was discovered by social media, and the pump was on, and I watched it head towards "da moon." When I saw that, I knew it was time to hit the sidelines, my first and only 4 bagger on a short term hold, figured I could buy in later if the drug actually had some promise, and likely around where I'd bought. News never was good enough to do that, and eventually started looking like the same sort of fluff you see all over the OTC.
Yup, one for 400, but .0025 for 1 sounds nicer,
Sooo...
That's 1:400...
RLFTF: .0025 to one reverse split:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
The shorts are licking their lips waiting for the RS. IMO
Getting to the NASDAQ will have zero benefit for the SH if the company doesn't have a viable product or service for sale. Lots of wannabes on the NASDAQ that get kicked back to the OTC for that reason. So, unless RAM has some other rabbit up his sleeve, r/s'ing to get to the NASDAQ will be a waste of time and money, and the experiment will cost the SH dearly. This will be RAM's opportunity to 'shine or fail miserably'.
Not at all pleased about this reverse split. Better not screw the shareholders
They need to stop talking about acquiring and expanding, and start PRing their intentions on generating revenues/profits. Enough is enough. I'm afraid the r/s will simply give them an excuse to keep spending and acquiring with no regard for the SH. Rinse, Repeat.
Seems to me this news would have made RLF a big mover
a year and a half back. I sort of think RLF needs some approvals for ARDS, C 19, etc, or team up with another company or country, like Japan, Korea, India, or a BP Swiss company
like Roche or Novartis.
.
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Relief Therapeutics Holding SA / Key word(s): Research Update
17-Apr-2023 / 07:00 CET/CEST
GENEVA (April 17, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or Relief), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced positive 12-month stability data for the liquid and lyophilized preparations of RLF-100®, intended for intravenous (IV) and inhaled administration. RLF-100® is the company’s proprietary, investigational formulation of aviptadil acetate.
The data from the stability study showed that both inhaled and IV RLF-100® demonstrated high purity levels at 12 months at all temperatures tested, including refrigerated and room temperature environments. The results are consistent with prior data observed at three- and six-month intervals. The stability testing study will continue to determine the maximum shelf life of RLF-100®.
Based on the latest results, Relief Therapeutics intends to amend its previously filed provisional patent application for RLF-100® with the new findings. If granted, this patent could provide exclusivity for RLF-100® at least until 2042, without considering Hatch-Waxman extensions or other patent term adjustments. The Hatch-Waxman Act permits a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process.
“The testing conducted to date has consistently shown that our novel, optimized composition of aviptadil acetate provides better stability results in both the liquid and lyophilized preparations. RLF-100® was shown to be shelf stable and active after one year at temperatures suitable for shipping and long-term storage. This is an important milestone toward commercialization to ensure that RLF-100® is safe and effective, no matter where in the world it is supplied.” said Jack Weinstein, chief executive officer at Relief Therapeutics. “We believe this new, stable formulation has significant clinical and commercial value and our goal is to establish RLF-100® as the standard of care for the prevention and treatment of respiratory failure and its complications in both the acute and chronic applications.”
Stability testing of pharmaceutical products is mandatory for regulatory approvals. If a product fails to meet the standards prescribed by regulatory authorities, the product will not be granted approval for commercialization. Planning, execution and completion of studies in given timelines plays a major role in securing approval and ensuring a product reaches patients who need it.
RLF-100® is under development for the potential treatment of acute and chronic lung diseases, including pulmonary sarcoidosis, infectious acute respiratory distress syndrome (ARDS), checkpoint inhibitor-induced pneumonitis (CIP) and chronic berylliosis. The U.S. Food and Drug Administration (FDA) granted RLF-100® Orphan Drug designation (ODD) to inhaled RLF-100® for the potential treatment of pulmonary sarcoidosis in August 2021.
https://www.relieftherapeutics.com/newsblog-detail/?newsID=2490653
Well said, I pulled the plug 2 years ago as I discovered that all this company was made of is just ….hot air…I made my money back with Ardelyx and Aurinia and expect much , much more coming from real research and real products…
I think I remember reading something about this some time back. Personally I think what is more important to investors today are current events. IMO there is not a lot to be optimistic about 'today' due to the upcoming R/S. Even if they make it to the NASDAQ, continued dilution will still crush the pps post R/S. I'm afraid that I've lost my trust in RAM and the RLFTF BOD. IMO RAM and the team are still too focused on expanding and creating new ventures than on turning the corner and focusing on generating revenues.
PennyWorld & friends, look closely at the FirstString link - https://www.crunchbase.com/organization/firststring-research Now https://xequel.com/
in 2016 a lot of "changes" were made by existing a) Relief Therapeutic and b) Relief Therapeutic HOLDING SA............Best short comment on this on SW."...................
In July 2016 THERAMetrics holding AG combined its business with Relief Therapeutics SA, moved its legal seat from Stans to Zurich, and changed its name to Relief Therapeutics Holding AG. During this transformation, in June 2016 the Company exited the CRO (contract research organization) business by selling its significant contract research subsidiaries to a larger global CRO. The Company's smaller CRO subsidiaries, where there was little or no business, were closed. I think one of those subsidiaries became FirstString Research, later changing its name to Xequel Bio. I don't know the full details of the changes because they are still private.
Translated with www.DeepL.com/Translator (free version)
https://twitter.com/search?q=Relief%20Therapeutics&src=typed_query&f=live
GENEVA, SWITZERLAND / ACCESSWIRE / April 5, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company committed to advancing treatment paradigms to benefit the lives of patients living with rare diseases, today announced that Nermeen Varawalla, M.D., Ph.D., chief medical officer, will depart the Company in the second quarter of 2023 to pursue other opportunities. The medical affairs team will report to Paolo Galfetti, chief operating officer at Relief Therapeutics, until a replacement is hired. Clinical development and regulatory responsibilities will continue to be supported by consultants already contracted with the Company.
"We have established strong medical affairs and research and development teams that will continue to serve us well as we focus our resources to advance our metabolic, connective tissue and pulmonary rare disease programs forward," said Jack Weinstein, chief executive officer at Relief Therapeutics. "We have moved our pipeline through several important milestones over the past year, and we appreciate Nermeen's contributions to those efforts. We wish Nermeen success in her future endeavors."
It would seem to me that RLFTF needs to NOW focus on generating sales and turning a profit off of their existing portfolio of drugs. Rather than pay more salaries and bonuses for more R&D in gene therapy. Where are the $$ going to come from to pay this person. Is RAM's vision a never ending black hole of R&D. It's time to start generating sales and moving toward a profit making enterprise. They are about to do an R/S, and we know where that will take us a year down the road. More dilution to pay for initiatives such as this. JMHO.
RT Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
https://www.relieftherapeutics.com/newsblog-detail/?newsID=2482011
GENEVA, APRIL 3, 2023 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company committed to advancing treatment paradigms to benefit the lives of patients living with rare diseases, today announces the appointment of world-renowned gene therapy pioneer Guangping Gao, Ph.D. as the chair of the Company’s newly formed scientific advisory board (SAB). Dr. Gao is the co-director of the Li Weibo Institute for Rare Diseases Research, director of the Horae Gene Therapy Center and Viral Vector Core, professor of microbiology and physiological systems, and Penelope Booth Rockwell Chair in biomedical research at the University of Massachusetts Chan Medical School in Worcester, Mass.
Internationally recognized in the field of gene therapy, Dr. Gao played a key role in the discovery and characterization of a new family of adeno-associated virus (AAV) serotypes, which was instrumental in reviving the gene therapy field, significantly impacting many currently untreatable human diseases.
“Dr. Gao is a distinguished and accomplished academic and genetic medicine leader who has made fundamental discoveries in gene therapy that have pushed the field forward. He brings an unparalleled combination of pioneering scientific research and pre-clinical and clinical gene therapy product development expertise, along with advanced viral vector manufacturing experience,” said Serene Forte, Ph.D., MPH, senior vice president, head of genetic medicine at Relief Therapeutics. “It will be a privilege to work with Dr. Gao and benefit from his vast knowledge and advice in this space.”
In his advisory role, Dr. Gao will serve as an integral resource, providing scientific review and high-level technical and strategic guidance related to gene therapy targets, research and pre-clinical development and strategic research alliances as the Company works to expand its portfolio.
“The Relief Therapeutics team has built a strong foundation with their current portfolio and cost-effective capital approach to drug development,” said Dr. Gao. “I look forward to working with Dr. Forte and the highly capable leadership team to help build and proficiently execute the Relief Therapeutics genetic medicine program.”
Relief Therapeutics launched its genetic medicines initiative with the objective of developing life-altering, potentially curative therapies for patients suffering from devastating rare diseases that currently lack treatment options. The company is leveraging its strength and experience to identify monogenic disorders in therapeutic areas that align with its areas of focus, such as rare metabolic diseases. The SAB will support the Company’s genetic medicines initiative and additional appointments are forthcoming. To learn more about Relief Therapeutics’ approach to genetic medicine, please visit: https://www.relieftherapeutics.com/genetic-medicine.
“Dr. Gao’s extensive experience in the advancement of novel approaches to treat inherited rare diseases will be instrumental in helping us shape the direction of our genetic medicine portfolio,” said Jack Weinstein, chief executive officer at Relief Therapeutics. “We are honored to have Dr. Gao lead our new SAB and welcome him to Relief Therapeutic
Well I hope that is not the case--but there are several new Rx from smaller cos that shareholders tend to believe that is case
Anyway--India is going thru some new covid strain/deaths so this might be great time to shine but I have not seen any data on Avip supply/dist/availability thru country
Would guess that what goes around will come around--once again (still) there is NOTHING in U.S. for S2C patients
They did not pay the FDA enough to approve it...
Couple of videos about ARDS and Avip
Our sibling foreign (RVVTF), tiny biotech is getting hammered today. Stagnation with the FDA process. Down to 4 cents now. Lot's of longs got burned over there just like lots of longs got burned here. Incompetence with senior mgmt there, just like here.
Would like to know what all Rx was tried and other issues
https://theprint.in/india/nursing-officer-dies-of-covid-in-rajasthans-bhilwara/1453286/
GENEVA, SWITZERLAND / ACCESSWIRE / February 14, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(ORCQB:RLFTY) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company developing and commercializing novel, patent-protected products in select specialty and rare diseases, announced today the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB).
Relief Therapeutics Holdings AG, Tuesday, February 14, 2023, Press release picture
Relief Therapeutics Holdings AG, Tuesday, February 14, 2023, Press release picture
The primary aim of this study will be to assess changes in the skin microbiome ( Staphylococcus aureus , Pseudomonas aeruginosa , commensal organisms) before, during and after treatment with RLF-TD011, a self-administered, sprayable solution enabling targeted application while avoiding skin contact and cross-contamination. Patients with dystrophic or junctional EB whose wounds are colonized by S. aureus and / or P. aeruginosa will be treated with RLF-TD011 for eight weeks followed by discontinuation of treatment for four weeks with assessment of their wound microbiome at each stage. All study participants will have the option to continue treatment in a six-month open-label study extension.
"EB is a rare, inherited skin disease characterized by widely distributed, painful, chronic wounds that easily become infected, resulting in an elevated risk of sepsis and death. As there is no cure for EB, a crucial element of patient management involves rigorous and timely wound care," said professor Amy Paller, M.D., chair, department of dermatology, Feinberg School of Medicine, Northwestern University and principal investigator of the study. "We are eager to assess the effect of RLF-TD011 on the microbiome in colonized dystrophic and junctional epidermolysis bullosa wounds and determine tolerability, symptom improvement, reduction of lesion size and wound closure."
The study is currently enrolling up to 17 patients diagnosed with junctional epidermolysis bullosa (JEB) or dystrophic epidermolysis bullosa (DEB) with S. aureus or P. aeruginosa culture-positive wounds at Ann & Robert H. Lurie Children's Hospital of Chicago.
"The results of this study will be most valuable for the swift, effective and efficient execution of our clinical development plan for RLF-TD011," said Nermeen Varawalla, M.D., Ph.D., chief medical officer, Relief Therapeutics. "These data will facilitate the design and conduct of follow-on, multi-center, pivotal registration clinical trials to determine the impact of RLF-TD011 on infection control, avoidance of chronic antibiotic use, accelerated wound healing and quality of life for patients living with EB."
Additional information about this investigator-initiated study is available at ClinicalTrials.gov ( NCT05533866 ).
ABOUT EPIDERMOLYSIS BULLOSA (EB)
Epidermolysis bullosa (EB), also known as "Butterfly Skin," is a group of rare, genetic, life-threatening connective tissue disorders characterized by skin fragility and blistering, which may appear in response to minor injury, even from heat, rubbing or scratching. In severe cases, the blisters may develop into chronic wounds or occur inside the body, such as the lining of the mouth or stomach. There are four main types of EB, which are classified based on the depth, or level, of blister formation: EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB) and Kindler syndrome. [1] Patients with JEB and DEB are at increased risk for serious complications, including aggressive squamous cell carcinoma. [2] Currently there is no cure or approved treatments for EB in the U.S.
The National Epidermolysis Bullosa Registry (NEBR) reports, based on 16 years of data, that the incidence of EB in the U.S. is 19.57 per 1 million live births and the prevalence is 11.07 per 1 million population. [3] Worldwide, EB impacts 500,000 lives. [4] The Company estimates the global market opportunity for EB to exceed $1.0 billion.
ABOUT RLF-TD011 (formerly known as APR-TD011)
RLF-TD011 (formerly known as APR-TD011) was developed using the TEHCLO ® proprietary technology and is a highly pure and stabilized hypochlorous acid (HClO >95% of free chlorine species), with pH between 2.5 - 3.0 and high reduction-oxidation potential (ORP 1.000 - 1.200 mV). It is a self-administered, sprayable solution enabling targeted application while avoiding skin contact and cross-contamination.
RLF-TD011 has consistently been shown to accelerate wound closure with reduced infection rates in clinical trials. [5] , [6] , [7] In a preliminary clinical trial, EB patients who administered RLF-TD011 demonstrated improvement in skin blistering and tissue repair within just two weeks of treatment, and the product candidate was shown to be well tolerated with a favorable safety profile.
RLF-TD011 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of EB, which qualifies the sponsor of the treatment for certain development incentives, including seven-year marketing exclusivity after FDA marketing approval is received. Relief Therapeutics intends to seek qualified infectious disease product (QIDP) designation status for RLF-TD011, which may confer up to an additional five years of market exclusivity regardless of patent protection status. If approved by the FDA in this indication, RLF-TD011 would be the first topical treatment specifically indicated to improve the microbiome in EB resulting in symptom control and halting disease progression.
RLF-TD011 is currently registered under the brand name Nexodyn ® AcidOxidizing Solution (AOS) for use in the debridement, irrigation, cleansing and moistening of chronic wounds and acute wounds, post-surgical wounds, cuts, abrasions, burns and other lesions. Nexodyn AOS is certified in the EU as a class III medical device and in the U.S. as a 510(k) cleared unclassified device.
ABOUT RELIEF THERAPEUTICS
Relief Therapeutics is a Swiss, commercial-stage, biopharmaceutical company focused on development and commercialization developing and commercializing novel, patent-protected products in select specialty and rare diseases, including metabolic disorders, pulmonary diseases and connective tissue disorders. Relief Therapeutics' diversified pipeline consists of assets that have the potential to effectively address significant unmet medical needs, including PKU GOLIKE ® , engineered with the proprietary Physiomimic™ technology, which is the first prolonged-release amino acid product commercialized for the dietary management of phenylketonuria (PKU). Relief Therapeutics has a collaboration and license agreement with Acer Therapeutics for the worldwide development and commercialization of Olpruva™ (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and maple syrup urine disease (MSUD). Relief Therapeutics continues to develop RLF-100 (aviptadil) for several pulmonary indications. Further, Relief Therapeutics is undertaking the clinical development of RLF-TD011 for the treatment of epidermolysis bullosa, an indication for which the FDA has granted orphan drug designation. Relief Therapeutics is also exploring the clinical development of RLF-TD011 for the treatment of cutaneous t-cell lymphomas. Finally, Relief Therapeutics is commercializing several legacy products via licensing and distribution partners.
RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY.
For more information, please visit www.relieftherapeutics.com or follow Relief Therapeutics on LinkedIn and Twitter .
FOR MEDIA/INVESTOR INQUIRIES CONTACT:
RELIEF THERAPEUTICS Holding SA
Catherine Day
Vice President, IR & Communications
contact@relieftherapeutics.com
LifeSci Advisors
Irina Koffler
+1-917-734-7387
ikoffler@lifesciadvisors.com
DISCLAIMER
This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether the study described above will be successful (ii) whether APR-TD011 (Nexodyn™ AOS) will ever be approved in the U.S., the U.K., or the E.U. for the treatment of EB or any other disease, and (iii) those risks discussed in RELIEF THERAPEUTICS Holding SA's press releases and filings with the SIX and with the U.S. Securities and Exchange Commission, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
REFERENCES
[1] National Institute of Arthritis and Musculoskelatal and Skin Diseases: Epidermolysis Bullosa. Accessed February 10, 2023. https://www.niams.nih.gov/health-topics/epidermolysis-bullosa.
[2] Condorelli AG, Dellambra E, Logli E, Zambruno G, Castiglia D. Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives. Int J Mol Sci. 2019 Nov 14;20(22):5707. doi: 10.3390/ijms20225707. PMID: 31739489; PMCID: PMC6888002.
[3] Fine J-D. Epidemiology of Inherited Epidermolysis Bullosa Based on Incidence and Prevalence Estimates From the National Epidermolysis Bullosa Registry. JAMA Dermatology . 2016;152(11):1231-1238. doi:10.1001/jamadermatol.2016.2473.
[4] EB Research Network: Understanding EB and its Classification. Accessed February 10, 2023. https://www.eb-researchnetwork.org/research/what-is-eb/.
[5] Iacopi E. et al. The Use of a Novel Super-Oxidized Solution on Top of Standard Treatment in the Home Care Management of Postsurgical Lesions of the Diabetic Foot Reduces Reinfections and Shortens Healing Time. Int J Low Extrem Wounds . 2018 Dec; 17(4):268-274.
[6] Strohal R, et al. The management of critically colonized and locally infected leg ulcers with an Acid-Oxidizing Solution: A pilot study. Adv Skin Wound Care 31(4):163-171, 2018.
[7] Ricci E, et al. The management of chronic ulcers with an AcidOxidizing Solution. J Wound Care 25(8):443-50, 2016.
SOURCE: Relief Therapeutics Holdings AG
View source version on accesswire.com:
https://www.accesswire.com/739259/Relief-Therapeutics-Announces-Enrollment-of-First-Three-Patients-in-Proof-of-Concept-Clinical-Trial-of-RLF-TD011-for-the-Treatment-of-Epidermolysis-Bullosa
cant really do anything, as usual, with this ticker but wait and see. Back into the long and lean bin.
Sold my entire position this morning. Taking it up the a— and running
For everyone who holds their position here good luck
I am not as averse to the reverse as many. Now if it is just to reverse/up price/ and dilute dilute then count me in as "against"
I get it takes funds to run trials and until there is suff cash flow--there are not a lot of options. The "debacle" with NRX CEO hurt. I think that NRX is a good company but that guy is scum.
But at some point that is/was RLFT mngmt decision. Poor decision--not worthy of full comp.
I would like to see ALL mngmt/board take a large% or ALL of comp in shares. Make everyone participate in a 10B-5 plan or ?? where the better the stock does, better for all shareholders. Not just the option,warrant,bonus award stuff get rewarded. Get some major skin in game.
Money out of everyone pocket--so we all feel the pain and all enjoy the gain
wordman....thanks for posting ..............
Detail description.
Aviptadil was shown to restore barrier function at the endothelial/alveolar interface and to protect the lung and other organs from failure. In Europe, Aviptadil is approved for human use and has been shown to be safe in phase II trials for sarcoidosis, pulmonary fibrosis, bronchospasm, erectile dysfunction as well as in a phase I trial in ARDS in the past two decades. In the US, VIP has been given FDA Orphan Drug Designation for the treatment of ARDS and was admitted to the FDA Corona Virus Technology Accelerator Program.
In a phase I trial of Aviptadil performed by Sami Said in the early 2000s, eight patients with severe ARDS on mechanical ventilation were treated with ascending doses of intravenous VIP. Seven patients (88%) were successfully extubated and were alive at the five day time point. Six (75%) left the hospital and one (13%) died of an unrelated cardiac event. A phase II clinical trial using intravenous Aviptadil in patients with COVID-19 infection and ARDS has begun. Further, a phase II/III clinical trial will study the effect of inhaled Aviptadil for the treatment of non-acute lung injury in COVID- 19 and begins in June 2020. In Europe, two phase II trials of Aviptadil have been conducted. Further, studies with healthy volunteers have shown that inhaled Aviptadil is well tolerated with few adverse effects.
Thanks for the update. Amazing that this trial is not scheduled for completion until Dec 2023. Which means we won't hear the formal results until we are deep into 2024....long after RAM pulls his R/S stunt.
There is truth to that. How exactly this will impact shareholders is still an unknown. If it works out well, it will—reduce the outstanding share count, increase the stock price, obtain listing on Nasdaq and hopefully draw in institutional investors.
The most significant downside of a reverse stock split is that it diminishes share liquidity in the market, and because illiquid shares are rarely traded, proper price discovery of the stock price may be hampered.
I may be wrong but I’ve heard often that reverse splits to not end well for the existing shareholders. Thoughts
In January 2023, changes to Swiss corporate law became effective allowing Swiss companies to reverse split their ordinary shares. Relief Therapeutics' board of directors will propose to shareholders to approve a reverse split of the Company's ordinary shares at a still to be determined ratio. An Extraordinary General Meeting (EGM) will be convened once ongoing preparations are in place. If the reverse split is completed successfully, Relief Therapeutics will file an application to list its ordinary shares on the Nasdaq Stock Market instead of its American depository shares (ADSs).
"Working with the Swiss and U.S. regulators, we believe efforts to complete a reverse split and then list our ordinary shares on the Nasdaq will positively benefit our shareholders, complementing our current primary listing of ordinary shares on the SIX Swiss Exchange," said Jack Weinstein, chief executive officer, Relief Therapeutics. "The current number of outstanding shares is in part the result of successive reverse mergers over the life of Relief's underlying listed vehicle. The reverse split will reduce the number of outstanding shares and is expected to increase the shares' attractiveness for investors while boosting the Company's public image."
RW 1 d380812drw.htm RW
RELIEF THERAPEUTICS HOLDING SA
Avenue de Secheron 15
CH-1202 Geneva
Switzerland
February 7, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, DC 20549
Re:
RELIEF THERAPEUTICS Holding SA
Registration Statement on Form F-1
(File No. 333-267026)
Ladies and Gentlemen:
Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), RELIEF THERAPEUTICS Holding SA, a corporation organized under the laws of Switzerland (the “Company”), hereby applies for the immediate withdrawal of the above-referenced Registration Statement on Form F-1, which was originally filed with the Securities and Exchange Commission (the “Commission”) on August 23, 2022, together with all amendments and exhibits thereto (the “Registration Statement”).
The Registration Statement was filed in connection with the proposed public offering by the Company of its American Depositary Shares, each representing 200 ordinary shares, par value CHF 0.01 per share, which the Company has determined not to pursue at this time. The Registration Statement has not been declared effective by the Commission. The Company confirms that it has not sold any securities pursuant to the Registration Statement.
The Company hereby requests an order granting the withdrawal of the Registration Statement to be issued by the Commission as soon as possible. Please provide a copy of the order granting withdrawal of the Registration Statement to the Chief Executive Officer of the Company, Jack Weinstein, Avenue de Secheron 15, CH-1202 Geneva, Switzerland, or via e-mail at jack.weinstein@relieftherapeutics.com, with a copy to the Company’s counsel, Philip B. Schwartz, Akerman LLP, 201 East Las Olas Boulevard, Suite 1800, Fort Lauderdale, FL 33301, or by e-mail at philip.schwartz@akerman.com.
The Company requests that, in accordance with Rule 457(p) promulgated under the Securities Act, all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company’s account for future use.
Please do not hesitate to call Philp Schwartz of Akerman LLP at (954) 468-2455 with any questions you may have regarding this matter.
Very Truly yours,
By: /s/ Jack Weinstein
Jack Weinstein, Chief Executive Officer
yes, I've read about that. However I haven't been able to locate a link to obtain more information on this. Have you?
As part of the FDA's Coronavirus Treatment Acceleration Program, Relief Therapeutics, a Swiss company, is examining the effectiveness of Aviptadil, a patented synthetic
version of a human vasoactive intestinal polypeptide (VIP), for
COVID-19-related ARDS at New York University Langone (NYU Langone Health)
(CTAP).
pegs1, I'm losing hope that any remaining aviptadil trials will make a difference on the RLFTF stock price. So I'm not following the trials as closely as I had in the past. I see treatment for ARDS as the only short term hope for SH. Maybe ACER if they can start generating sales now that ACER 001 has been approved.
This trial was supposed to have completed by Dec 2022, so I would suspect that we'll hear something about those results. https://clinicaltrials.gov/ct2/show/NCT04536350
I'm still waiting for the formal release of the NIH trial results.
I'm not aware of any 'ongoing' aviptadil trial that is seeking new patients. Sorry. Have you tried reaching out directly to RLFTF for any information on ongoing trials?
Pegs maybe this recent article is helpful.............
insert-text-here
Continued prayers pegs….
Followers
|
393
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
44695
|
Created
|
07/01/20
|
Type
|
Free
|
Moderators |
Dr. Sami Said"The Son of a Coptic Priest & Discoverer of VIP"
Dr. Sami Said's Obiturary Vasoactive Intestinal Peptide - Robert J. Henning, in Handbook of Biologically Active Peptides (Second Edition) 2013 Shoemaker Project RLF-100™ is a synthetic form of Vasoactive Intestinal Peptide (VIP) consisting of 28 amino acids which was first discovered in 1970. Although initially identified in the intestinal tract, human VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. Here VIP has shown a multimodal mechanism of action: inhibition of viral replication, deterrence of inflammatory cytokines, prevention of cell death and upregulation of surfactant production. 70% of the VIP in the body is bound to a rare cell in the lung, the alveolar type 2 cell, which is critical to the transmission of oxygen to the body. RLF-100™ has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension. It has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury and inflammation. RLF-100™ is currently in clinical testing for acute lung injury (ALI) associated with the SARS-CoV-2 virus (COVID-19).
• Relief Therapeutics has demonstrated some very very compelling results against COVID19 - Prestige World Wide! Wide ...Wide..Wide... | Corporate Information
Leadership
![]() Videos, Conferences & Webcasts 10/15/2020 Solebury Trout Video with Transcript https://sites.google.com/view/aguyus | HistoryDr. Said->Stony Brook->Mondo Biotech->Therametrics->Relief AGMondobiotech10 Orphan Drugs in EU and US 19 Patents Granted 81 medicinal Products candidates 22 patent Families filed 312 Peptides to Redirect in Rare disease Mondo Biotech Patents WIPO IP PORTAL PAtentscope Search = Mondobiotech Total Hits 898 - RSS 2012-04-054/5/2012 Annual Report Mondobiotech 2011 Page 10 Unlisted Companies Therametrics 6/20/2013 MondoBiotech holding AG changes name Therametrics Holding AG “ The company changed its name from mondoBIOTECH holding AG to THERAMetrics holding AG as at 20 June 2013” Notes to the Financial Statements see 1. General Information Page 7 2014-05-14 THERAMetrics Holding AG - Listed as TMX on Swiss SIX |
Status | Study Title | Conditions | Interventions | Locations |
---|---|---|---|---|
Completed | Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure |
|
|
|
Recruiting | Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS |
|
|
|
Recruiting | A Clinical Study Evaluating Inhaled Aviptadil on COVID-19 |
|
|
|
Available | ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE) |
|
|
|
Recruiting | Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 |
|
|
|
Recruiting | ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 |
|
|
|
Volume: | 2,152 |
Day Range: | 2.39 - 2.76 |
Last Trade Time: | 3:52:53 PM EDT |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |